Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q1 FY27
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q3 FY25
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
900.00 | 7,274 Cr | 36.67 | 6.07 | 0.11 | 17.46 | 23.00 | 14.62 | ||
3080.00 | 7,093 Cr | 19.64 | 8.59 | 3.99 | 39.20 | 51.99 | 23.01 | ||
1472.55 | 6,758 Cr | 51.66 | 7.24 | 0.00 | 12.36 | 14.43 | 8.16 | ||
1153.10 | 6,556 Cr | 42.56 | 6.01 | 0.17 | 12.92 | 14.30 | 8.38 | ||
196.10 | 6,364 Cr | 4.02 | 4.75 | 0.00 | 116.01 | 80.89 | 72.98 | ||
115.95 | 6,354 Cr | 45.19 | 5.10 | 0.17 | 5.96 | 7.58 | 7.26 | ||
515.15 | 6,343 Cr | 26.84 | 13.58 | 0.88 | 47.50 | 52.11 | 35.05 | ||
| Median: 7 Co. | — | 900.00 | 6,556 Cr | 36.67 | 6.07 | 0.17 | 17.46 | 23.00 | 14.62 |
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas.
Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth.
The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations.
The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets.
Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,514 Cr
Low Risk
49.8
37.4
1.6
7.2
1,599.55
661.65
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Senores Pharmaceuticals Ltd (SENORES) is currently trading at 1,414.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas. Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth. The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations. The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets. Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹661.65 and a high of ₹1,599.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Senores Pharmaceuticals Ltd has a market capitalization of approximately 6,758.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Senores Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.66 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,758.13 Cr, Senores Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Senores Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 51.66. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company reported consolidated total income of ₹138.0 crore in Q1 FY26, up 72% year-on-year, as stated in the provided release and investor highlights.
The results are expected in the July to August 2026 window (indicative), in line with the broader NSE and BSE results season for the quarter ended June 2026.
The Q1 FY27 earnings conference call is scheduled for Monday, July 27, 2026, at 5:15 PM IST.
The call is scheduled for July 27, 2026, starting at 05:15 PM IST to discuss the quarter ended June 30, 2026.
Bearish
3
Neutral
7
Bullish
4
Bearish
25
Neutral
7
Bullish
14
Bearish
22
Neutral
0
Bullish
10
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
7
Bullish
4
Bearish
22
Neutral
0
Bullish
10
Bearish
22
Neutral
0
Bullish
10
Bearish
22
Neutral
0
Bullish
10
